Sanofi (SNY) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

SNY · Stock Price

USD 43.18-6.72 (-13.47%)

Market Cap: $102.8B

Historical price data

Market Cap: $102.8BPipeline: 200 drugs (32 Phase 3)Patents: 20Founded: 1973Employees: 90,000-100,000HQ: Paris, France

Sector Ranking#38 in Biologics / Biosimilars #4 in AI / Machine Learning

Overview

Sanofi is a global biopharmaceutical leader with a mission to 'chase the miracles of science' by developing innovative medicines and vaccines. The company has strategically pivoted to become an R&D-driven, AI-powered organization, focusing its deep immunoscience expertise on high-growth areas like immunology and oncology. Its strategy is centered on accelerating drug discovery, optimizing its robust pipeline, and delivering compelling growth through breakthrough therapeutics.

ImmunologyOncologyRare DiseasesNeurologyVaccines

Technology Platform

Sanofi's core platform integrates deep immunoscience expertise with a pervasive artificial intelligence (AI) engine deployed across the entire R&D value chain, from target discovery to clinical development optimization.

Pipeline

200

200 drugs in pipeline32 in Phase 3

Drug	Indication	Stage
Insulin glargine + 75% insulin lispro protamine suspension a...	Diabetes Mellitus, Type 2	Phase 3
LACTIC ACID(ND)	Hygiene	Phase 3
gemcitabine/Eloxatin (GEMOX) + carboplatin/paclitaxel (CP)	Carcinoma, Non-Small-Cell Lung	Phase 3
Insulin glargine (HOE901) + NPH insulin	Type 1 Diabetes Mellitus	Phase 3
Lixisenatide (AVE0010) + Metformin	Type 2 Diabetes Mellitus	Phase 3

FDA Approved Drugs

34

MERILOGBLAFeb 14, 2025

MERILOG SOLOSTARBLAFeb 14, 2025

FEXINIDAZOLENDAJul 16, 2021

Opportunities

Significant near-term growth is anchored by the potential expansion of Dupixent into COPD and the launch of amlitelimab in immunology.

Long-term, the application of mRNA technology to influenza and combination vaccines represents a multi-billion dollar market disruption opportunity.

Risk Factors

Key risks include clinical or regulatory setbacks for pivotal late-stage assets like Dupixent in COPD, intense competitive pressure across all core therapeutic areas, and ongoing pricing headwinds from global healthcare cost containment policies.

Competitive Landscape

Sanofi faces intense competition from large-cap peers (AbbVie, J&J, Pfizer, GSK) in immunology, oncology, and vaccines, as well as from agile biotech innovators. Its strategy relies on AI-driven R&D speed, deep biologics expertise, and global commercial scale to differentiate.